Proactive Investors - Run By Investors For Investors

Scancell surges after announcing milestone in development of its solid tumours treatment

Scancell has a clinical development partnership with Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research
Cancer article in a newspaper
Scancell's ImmunoBody immunotherapy platform activates the body's immune system

Scancell Holdings PLC (LON:SCLP) and the cancer charity Cancer Research UK have announced further progress with Scancell's SCIB2 cancer immunotherapy vaccine.

Pre-clinical studies have demonstrated that the administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.

READ Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The nanoparticle technology uses known lipid (soluble biomolecules) carriers that are optimised to deliver SCIB2 DNA to immune cells. The liposomal nanoparticles protect the DNA from degradation and facilitate efficient uptake, expression and T-cell activation against cancer cells, said Scancell.

The nanoparticle delivery system provides an alternative approach to electroporation - an electrical technique that involves the application of high-voltage electric pulses in short bursts – that has been used to deliver other ImmunoBody agents to patients.

Cancer Research UK is now planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

Dr Cliff Holloway, the chief executive officer of Scancell, said the latest milestone “moves us one step closer to entering the clinic”.

“This new nanoparticle approach to deliver SCIB2 is expected to achieve results that are as effective as, or even better than, electroporation. We believe SCIB2 has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours including NSCLC, the most frequent cause of cancer death globally,” Holloway added.

Dr Nigel Blackburn, Cancer Research UK's director of drug development, said the vaccine could bring about urgently needed improvements for some cancer treatments.

“Our collaboration with Scancell, combining extensive expertise and experience in drug development, will help bring this treatment to the patients that need it sooner,” Blackburn declared.

Shares in Scancell were up 12% at 4.75p in early deals.

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
September 17 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use